# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
icad (NASDAQ:ICAD) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. The company report...
iCAD, Inc. (NASDAQ:ICAD) a global leader in clinically proven AI-powered cancer detection solutions, today announced a strategi...
icad (NASDAQ:ICAD) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67...